AGL

BTIG cuts its price target on Humacyte (HUMA) but maintains a Buy rating, citing a larger long-term opportunity despite near-term challenges. The stock movement reflects this mixed analyst sentiment.

AI-generated: summaries written by AI from the linked sources. How we use AI